DEA Rescheduling Hearing: Week 1 Recap
One week into the DEA's administrative hearing on federal rescheduling, the proceedings have been far more technical than political. While the hearing has generated criticism for its lack of transparency (it is not livestreamed), it has produced few dramatic moments. Instead, attorneys, scientists, and medical experts are building what will likely become the administrative record that ultimately determines whether moving from Schedule I to Schedule III can survive judicial review.
DEA Defends S3?
Government lawyers have repeatedly stated that they are the proponents of the proposed rule and are presenting evidence to support the Department of Health and Human Services' conclusion that the plant has a currently accepted medical use. Their witnesses have focused on the scientific review conducted by HHS, the role of state-regulated medical programs, and evidence supporting medical use for chronic pain. They have also made it clear that the hearing is not about legalization or adult-use markets, but whether it meets the legal standard for Schedule III under the Controlled Substances Act.
The seven designated outside participants all oppose broader rescheduling, but their strategy has been notably restrained.
Rather than arguing that it has no medical value, they have concentrated on challenging the government's scientific methodology. Cross-examinations have focused on whether HHS applied the correct legal standard for "currently accepted medical use," whether the available clinical evidence is sufficient, and whether state medical programs should be considered evidence of accepted medical practice.
The Overall Tone
Unlike a Congressional hearing, there have been no televised exchanges or headline-grabbing confrontations. The courtroom has instead resembled a technical administrative proceeding, with careful witness examinations, evidentiary objections, and discussions centered on statutory interpretation rather than politics.
Every indication suggests the participants understand the real audience may ultimately be a federal appellate court. That has led both sides to focus less on public messaging and more on building—or dismantling—the legal record.
What to Expect This Week
As the hearing resumes following the Independence Day recess, the focus is expected to shift toward more aggressive cross-examination of the government's remaining witnesses.
Key issues to watch include:
Whether opponents can expose weaknesses in HHS's scientific and medical evaluation.
Continued debate over the definition of "currently accepted medical use."
Additional testimony regarding the role of state medical programs in establishing accepted medical practice.
Procedural rulings by the Administrative Law Judge that could become important if the final rule is challenged in court.
The hearing is expected to conclude by July 15, after which the Administrative Law Judge will compile the evidentiary record and issue a recommended decision. The recommendation is advisory; the final scheduling decision remains with the DEA Administrator and the Department of Justice. Regardless of the outcome, legal challenges are widely expected from one or more parties.
